Osalmid Inhibits the Progression of Lung Adenocarcinoma and Sensitizes It to EGFR-TKIs: A Preclinical and Translational Study

被引：0
|
作者：
Wu, L. -L. [1 ]
Jiang, W. -M. [1 ]
Wang, R. -R. [2 ]
Xie, D. [2 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Shanghai Pulm Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.03I.14
引用
收藏
页码：S315 / S315
页数：1
相关论文
共 50 条
  • [31] Effect of EGFR-TKIs Combined with Cerebral Radiotherapy on Prognosis of Patients with EGFR-Mutant Lung Adenocarcinoma with Brain Metastasis
    Deng, G.
    Li, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S164 - S164
  • [32] Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated with EGFR-TKIs
    Kim, I. A.
    Kim, H. J.
    Lee, J. S.
    Lee, K. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2138 - S2138
  • [33] Compared with the difference in efficacy between EGFR-TKIs alone and EGFR-TKIs combined with craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastasis. A propensity-score matched analysis
    Deng, G.
    Li, Z.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1012 - S1012
  • [34] Metformin plus EGFR TKIs for lung adenocarcinoma
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (10): : E563 - E563
  • [35] Clinical efficacy and safety of apatinib combined with EGFR-TKIs in advanced non-small cell lung cancer with EGFR-TKIs resistance
    Tian, Ruifen
    Guo, Yi
    Zhang, Xia
    Zhang, Xing
    Guo, Wei
    Zhu, Haibo
    Xu, Junjun
    Shen, Fangfang
    Song, Xia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] METFORMIN PROLONGS SURVIVAL IN LUNG CANCER EGFR-TKIS PATIENTS
    Hung, Ming-Szu
    Chuang, Min-Chun
    Yang, Yao-Hsu
    Lung, Jrhau
    Tsai, Ying-Huang
    RESPIROLOGY, 2018, 23 : 171 - 171
  • [37] EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
    Milovancev, Aleksandar
    Stojsic, Vladimir
    Zaric, Bojan
    Kovacevic, Tomi
    Sarcev, Tatjana
    Perin, Branislav
    Zarogoulidis, Konstantinos
    Tsirgogianni, Katerina
    Freitag, Lutz
    Darwiche, Kaid
    Tsavlis, Drosos
    Zissimopoulos, Athanasios
    Stratakos, Grigoris
    Zarogoulidis, Paul
    ONCOTARGETS AND THERAPY, 2015, 8 : 2915 - 2921
  • [38] Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
    Zhou, Jinhua
    Qin, Hongya
    Miao, Jianlong
    Liu, Ruijuan
    Wang, Wei
    MEDICINE, 2023, 102 (26) : E34110
  • [39] Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
    Yang, M.
    Li, J.
    Zhang, N.
    Xing, H.
    Liu, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Leukocyte telomere length is associated with survival and drug resistance in lung adenocarcinoma patients treated with EGFR-TKIs
    Yang, M.
    Li, J.
    Zhang, N.
    ANNALS OF ONCOLOGY, 2018, 29
12345